315 related articles for article (PubMed ID: 37085573)
1. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
Kouverianos I; Angelopoulos A; Daoussis D
Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
[TBL] [Abstract][Full Text] [Related]
2. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
[TBL] [Abstract][Full Text] [Related]
3. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis.
Yamada Y; Harada M; Hara Y; Iwabuchi R; Hashimoto K; Yamamoto S; Kamijo Y
Arthritis Res Ther; 2021 Jan; 23(1):28. PubMed ID: 33446268
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilic granulomatosis with polyangiitis.
Villa-Forte A
Postgrad Med; 2023 Jan; 135(sup1):52-60. PubMed ID: 36259957
[TBL] [Abstract][Full Text] [Related]
7. Eosinophilic granulomatosis with polyangiitis: A review.
White J; Dubey S
Autoimmun Rev; 2023 Jan; 22(1):103219. PubMed ID: 36283646
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
10. Hypertrophic pachymeningitis in eosinophilic granulomatosis with polyangiitis.
Izuka S; Yamashita H; Takahashi Y; Kaneko H
Mod Rheumatol Case Rep; 2022 Jan; 6(1):80-82. PubMed ID: 34480185
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
Ennis D; Lee JK; Pagnoux C
Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
[TBL] [Abstract][Full Text] [Related]
13. Update on eosinophilic granulomatosis with polyangiitis.
Furuta S; Iwamoto T; Nakajima H
Allergol Int; 2019 Oct; 68(4):430-436. PubMed ID: 31266709
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
15. Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
Ide H; Shimizu T; Koike Y; Abe K; Shigematsu K; Nishihata S; Kojima K; Ichinose K; Kawakami A
Medicine (Baltimore); 2022 Nov; 101(44):e31401. PubMed ID: 36343053
[TBL] [Abstract][Full Text] [Related]
16. ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics.
Piga MA; Fraticelli P; Antonicelli L; Garritani MS; Ghirelli G; Martini M; Di Vincenzo A; Danieli MG; Moroncini G; Bilò MB
Front Immunol; 2023; 14():1325299. PubMed ID: 38090592
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
18. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
19. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis.
Ozola L; Aleksejeva E; Stoldere D; Dāvidsone Z; Šantere R; Grantiņa I; Cīrule I; Krams A
Pediatr Pulmonol; 2023 Mar; 58(3):973-979. PubMed ID: 36404638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
